$CDZI
CADIZ INC Stock $cdzi

$cdzi Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000143774921007331 Filed on March 26, 2021

Income Statement

Concept	2020 Q4	2020	2019 Q4
Revenue	$140.0K	$541.0K	$111.0K
YoY Change	26.13%	22.68%	0.0%
Cost Of Revenue
YoY Change
Gross Profit			$111.0K
YoY Change			0.0%
Gross Profit Margin			100.0%
Selling, General & Admin	$2.310M	$11.90M	$2.960M
YoY Change	-21.96%	-2.46%	-26.73%
% of Gross Profit			2666.67%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$100.0K	$381.0K	$70.00K
YoY Change	42.86%	43.77%	0.0%
% of Gross Profit			63.06%
Operating Expenses	$2.410M	$12.30M	$3.020M
YoY Change	-20.2%	-0.81%	-26.34%
Operating Profit		-$11.75M	-$2.912M
YoY Change		-1.96%	-27.05%
Interest Expense	-$4.350M	$11.53M	-$4.130M
YoY Change	5.33%	-32.49%	2.23%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$6.620M	-$35.64M	-$7.040M
YoY Change	-5.97%	22.76%	-12.33%
Income Tax	$0.00	$7.000K	$0.00
% Of Pretax Income
Net Earnings	-$8.020M	-$37.80M	-$7.350M
YoY Change	9.12%	28.14%	-8.47%
Net Earnings / Revenue	-5728.57%	-6987.06%	-6621.62%
Basic Earnings Per Share
Diluted Earnings Per Share	-$253.5K	-$1.105M	-$268.2K
COMMON SHARES
Basic Shares Outstanding	35.54M		27.00M
Diluted Shares Outstanding		34.19K

Balance Sheet

Concept	2020 Q4	2020	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.300M	$7.300M	$15.70M
YoY Change	-53.5%	-53.5%	24.6%
Cash & Equivalents	$7.290M	$7.300M	$15.68M
Short-Term Investments
Other Short-Term Assets	$700.0K	$700.0K	$400.0K
YoY Change	75.0%	75.0%	0.0%
Inventory
Prepaid Expenses
Receivables	$55.00K	$100.0K	$49.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$8.036M	$8.000M	$16.12M
YoY Change	-50.14%	-50.31%	23.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$53.48M	$53.50M	$49.95M
YoY Change	7.08%	7.0%	7.14%
Goodwill	$3.813M		$3.813M
YoY Change	0.0%		0.0%
Intangibles
YoY Change
Long-Term Investments	$1.354M	$1.400M	$729.0K
YoY Change	85.73%	100.0%
Other Assets	$4.530M	$7.700M	$4.118M
YoY Change	10.0%	26.23%	6.33%
Total Long-Term Assets	$66.33M	$66.40M	$60.61M
YoY Change	9.44%	9.57%	7.64%
TOTAL ASSETS
Total Short-Term Assets	$8.036M	$8.000M	$16.12M
Total Long-Term Assets	$66.33M	$66.40M	$60.61M
Total Assets	$74.36M	$74.40M	$76.72M
YoY Change	-3.08%	-3.0%	10.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$548.0K	$500.0K	$194.0K
YoY Change	182.47%	150.0%	-13.78%
Accrued Expenses	$674.0K	$700.0K	$4.536M
YoY Change	-85.14%	-84.78%	119.13%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$51.00K	$100.0K	$31.00K
YoY Change	64.52%		-47.46%
Total Short-Term Liabilities	$3.135M	$3.100M	$4.805M
YoY Change	-34.76%	-35.42%	16.01%
LONG-TERM LIABILITIES
Long-Term Debt	$78.60M	$78.60M	$137.6M
YoY Change	-42.87%	-42.88%	0.97%
Other Long-Term Liabilities	$0.00	$17.90M	$15.00K
YoY Change	-100.0%	8.48%
Total Long-Term Liabilities	$78.60M	$96.50M	$137.6M
YoY Change	-42.87%	-37.38%	0.98%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.135M	$3.100M	$4.805M
Total Long-Term Liabilities	$78.60M	$96.50M	$137.6M
Total Liabilities	$99.66M	$99.70M	$158.8M
YoY Change	-37.26%	-37.22%	2.12%
SHAREHOLDERS EQUITY
Retained Earnings	-$539.4M		-$501.6M
YoY Change	7.54%		6.72%
Common Stock	$368.0K		$285.0K
YoY Change	29.12%		15.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$25.30M	-$25.30M	-$82.12M
YoY Change
Total Liabilities & Shareholders Equity	$74.36M	$74.40M	$76.72M
YoY Change	-3.08%	-3.0%	10.7%

Cashflow Statement

Concept	2020 Q4	2020	2019 Q4
OPERATING ACTIVITIES
Net Income	-$8.020M	-$37.80M	-$7.350M
YoY Change	9.12%	28.14%	-8.47%
Depreciation, Depletion And Amortization	$100.0K	$381.0K	$70.00K
YoY Change	42.86%	43.77%	0.0%
Cash From Operating Activities	-$3.130M	-$13.43M	-$3.010M
YoY Change	3.99%	-2.04%	-15.21%
INVESTING ACTIVITIES
Capital Expenditures	-$630.0K	$5.729M	-$170.0K
YoY Change	270.59%	258.29%	-63.83%
Acquisitions
YoY Change
Other Investing Activities	-$1.400M	-$4.110M	-$900.0K
YoY Change	55.56%	356.67%	-55.0%
Cash From Investing Activities	-$2.030M	-$9.838M	-$1.070M
YoY Change	89.72%	293.05%	-56.68%
FINANCING ACTIVITIES
Cash Dividend Paid		$0.00
YoY Change
Common Stock Issuance & Retirement, Net		$14.77M
YoY Change		-23.86%
Debt Paid & Issued, Net		$43.00K
YoY Change		-27.12%
Cash From Financing Activities	4.940M	$14.87M	4.490M
YoY Change	10.02%	-23.08%	393.41%
NET CHANGE
Cash From Operating Activities	-3.130M	-$13.43M	-3.010M
Cash From Investing Activities	-2.030M	-$9.838M	-1.070M
Cash From Financing Activities	4.940M	$14.87M	4.490M
Net Change In Cash	-220.0K	-$8.392M	410.0K
YoY Change	-153.66%	-368.54%	-108.02%
FREE CASH FLOW
Cash From Operating Activities	-$3.130M	-$13.43M	-$3.010M
Capital Expenditures	-$630.0K	$5.729M	-$170.0K
Free Cash Flow	-$2.500M	-$19.16M	-$2.840M
YoY Change	-11.97%	25.15%	-7.79%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	38342952
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	7531
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	7531
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	70000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	70000000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36902361
CY2019Q4	us-gaap	Equity Method Investments EquityMethodInvestments	729000	USD
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36902361
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28480567
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28480567
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2013Q1	cdzi	Number Of Milestones For Common Stock Issuance NumberOfMilestonesForCommonStockIssuance	2	pure
CY2013Q1	cdzi	Shares Payable Term From Date Earned SharesPayableTermFromDateEarned	P3Y
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2020	us-gaap	Revenues Revenues	541000	USD
CY2019	us-gaap	Revenues Revenues	441000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11914000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12165000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	381000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	265000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	12295000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	12430000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-11754000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-11989000	USD
CY2020	us-gaap	Interest Expense InterestExpense	11526000	USD
CY2019	us-gaap	Interest Expense InterestExpense	17072000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	33000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	226000	USD
CY2020	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	-0	USD
CY2019	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	197000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-12394000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-35641000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-29032000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6000	USD
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2169000	USD
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-490000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-37817000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-29528000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.11
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.11
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34188
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26549
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7290000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15682000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	55000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	49000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	691000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	386000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	8036000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	16117000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	53481000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	49947000	USD
CY2020Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	3000000	USD
CY2019Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	2000000	USD
CY2020Q4	us-gaap	Equity Method Investments EquityMethodInvestments	1354000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	3813000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17183000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15707000	USD
CY2020Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	750000	USD
CY2019Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	750000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4805000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	78596000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	137565000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	3813000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4679000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4118000	USD
CY2020Q4	us-gaap	Assets Assets	74363000	USD
CY2019Q4	us-gaap	Assets Assets	76724000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	548000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	194000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	674000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4536000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	51000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	31000	USD
CY2020Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1847000	USD
CY2019Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	15000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	44000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3135000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	15000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	99664000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	158842000	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	368000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	285000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	513744000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	419194000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-539414000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-501597000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-25301000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-82118000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	74363000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	76724000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-37817000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-29528000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	381000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	265000	USD
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	766000	USD
CY2019	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	81000	USD
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	296000	USD
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3856000	USD
CY2020	cdzi	Paid In Kind Interest Added To Loan Principal PaidInKindInterestAddedToLoanPrincipal	7270000	USD
CY2019	cdzi	Paid In Kind Interest Added To Loan Principal PaidInKindInterestAddedToLoanPrincipal	10031000	USD
CY2020	cdzi	Paid In Kind Interest Added To Lease Liability PaidInKindInterestAddedToLeaseLiability	1451000	USD
CY2019	cdzi	Paid In Kind Interest Added To Lease Liability PaidInKindInterestAddedToLeaseLiability	1272000	USD
CY2020	cdzi	Income Loss From Equity Method Investments Excluding Investing Activities IncomeLossFromEquityMethodInvestmentsExcludingInvestingActivities	-2169000	USD
CY2019	cdzi	Income Loss From Equity Method Investments Excluding Investing Activities IncomeLossFromEquityMethodInvestmentsExcludingInvestingActivities	-490000	USD
CY2020	cdzi	Gains Losses On Debt Conversion And Extinguishment Of Debt GainsLossesOnDebtConversionAndExtinguishmentOfDebt	-12394000	USD
CY2019	cdzi	Gains Losses On Debt Conversion And Extinguishment Of Debt GainsLossesOnDebtConversionAndExtinguishmentOfDebt	-38000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1508000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-729000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13428000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13708000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5729000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1599000	USD
CY2020	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	3109000	USD
CY2019	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	904000	USD
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1000000	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	-0	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9838000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2503000	USD
CY2020	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	0	USD
CY2019	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	197000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	2096000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	562000	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-139000	USD
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	305000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-22000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	605000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	186000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	129000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-68000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14767000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	19395000	USD
CY2020	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	150000	USD
CY2019	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	USD
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	43000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	59000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14874000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19336000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8392000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3125000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15816000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12691000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7424000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15816000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-86240000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	19395000	USD
CY2019	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	12828000	USD
CY2019	cdzi	Current Period Reclassification Adjustment CurrentPeriodReclassificationAdjustment	865000	USD
CY2019	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	-0	USD
CY2019	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	562000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-29528000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-82118000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14767000	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	38900000	USD
CY2020	cdzi	Current Period Reclassification Adjustment CurrentPeriodReclassificationAdjustment	-865000	USD
CY2020	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2096000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-37817000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	38000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-25301000	USD
CY2020Q4	us-gaap	Area Of Land AreaOfLand	45000	acre
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-37800000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-29500000	USD
CY2020Q4	cdzi	Working Capital WorkingCapital	4900000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13400000	USD
CY2020Q4	cdzi	Required Payment To Acquire Property Available For Purchase Due End Of Fiscal Year RequiredPaymentToAcquirePropertyAvailableForPurchaseDueEndOfFiscalYear	19000000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates in Preparation of Financial Statements</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In preparing these financial statements, management has made estimates with regard to goodwill and other long-lived assets, stock compensation and deferred tax assets. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2020	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	2956081
CY2019	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	11477000
CY1988Q2	us-gaap	Goodwill Goodwill	7006000	USD
CY2020	cdzi	Goodwill Amortized Portion GoodwillAmortizedPortion	3193000	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020Q4	us-gaap	Goodwill Goodwill	3800000	USD
CY2020Q4	cdzi	Percentage Of Future Quarterly Interest Payments PercentageOfFutureQuarterlyInterestPayments	0.25	pure
CY2020	cdzi	Interest Payments In Stock InterestPaymentsInStock	1460000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7290000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15682000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	134000	USD
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	134000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7424000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15816000	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	7000	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	6000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	60545000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	56640000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7064000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6693000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	53481000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	49947000	USD
CY2020Q4	cdzi	Prepaid Rent Noncurrent PrepaidRentNoncurrent	4110000	USD
CY2019Q4	cdzi	Prepaid Rent Noncurrent PrepaidRentNoncurrent	3925000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	59000	USD
CY2020Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	554000	USD
CY2019Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	134000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4679000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4118000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	240000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	628000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	104000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	510000	USD
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	71000	USD
CY2019Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	71000	USD
CY2020Q4	cdzi	Accrued Liabilities Related To Well Development AccruedLiabilitiesRelatedToWellDevelopment	113000	USD
CY2019Q4	cdzi	Accrued Liabilities Related To Well Development AccruedLiabilitiesRelatedToWellDevelopment	1038000	USD
CY2020Q4	cdzi	Accrued Liabilities Related To Northern Pipeline Quality Test AccruedLiabilitiesRelatedToNorthernPipelineQualityTest	0	USD
CY2019Q4	cdzi	Accrued Liabilities Related To Northern Pipeline Quality Test AccruedLiabilitiesRelatedToNorthernPipelineQualityTest	1868000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	146000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	421000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	674000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4536000	USD
CY2020Q4	us-gaap	Other Loans Payable OtherLoansPayable	152000	USD
CY2019Q4	us-gaap	Other Loans Payable OtherLoansPayable	45000	USD
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	366000	USD
CY2019Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	304000	USD
CY2020Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	78647000	USD
CY2019Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	137596000	USD
CY2020Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	51000	USD
CY2019Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	31000	USD
CY2020Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	78596000	USD
CY2019Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	137565000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	51000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	78898000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	26000	USD
CY2020Q4	cdzi	Longterm Debt Maturities Repayments Of Principal In Year Five And Thereafter LongtermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter	0	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	79013000	USD
CY2020Q1	cdzi	Debt Instrument Prepayment Premium Percent DebtInstrumentPrepaymentPremiumPercent	0.07	pure
CY2020Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2020Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2000000.0	USD
CY2020Q1	cdzi	Reclassification Of Warrant Liability To Additional Paidin Capital ReclassificationOfWarrantLiabilityToAdditionalPaidinCapital	900000	USD
CY2020Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1100000	USD
CY2020Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	139000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	75303000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	70202000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4555000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4547000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	32000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	30000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits	1289000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits	1098000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	303000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	271000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	81482000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	76148000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	81482000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	76148000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5334000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4148000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1200000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-7940000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6200000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	3617000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	2508000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	7000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	6000	USD
CY2020	cdzi	Effective Income Tax Rate Reconciliation Expiring Carryforwards EffectiveIncomeTaxRateReconciliationExpiringCarryforwards	1547000	USD
CY2019	cdzi	Effective Income Tax Rate Reconciliation Expiring Carryforwards EffectiveIncomeTaxRateReconciliationExpiringCarryforwards	2427000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	2776000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1265000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6000	USD
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	70000000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36902361
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28480567
CY2013Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	400000
CY2013Q1	cdzi	Percentage Of Projects Annual Capacity PercentageOfProjectsAnnualCapacity	0.51	pure
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	115000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	492500
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.66
CY2018	cdzi	Options Outstanding Balance Average Remaining Contractual Term OptionsOutstandingBalanceAverageRemainingContractualTerm	P1Y3M18D
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3834000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2019	cdzi	Sharebased Compensation Arrangement By Sharebased Payment Award Options Forfeited Or Expirations Aggregate Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrExpirationsAggregateIntrinsicValue	0	USD
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	492500
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.66
CY2019	cdzi	Options Outstanding Balance Average Remaining Contractual Term OptionsOutstandingBalanceAverageRemainingContractualTerm	P0Y3M18D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3834000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	377500
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	11.50
CY2020	cdzi	Sharebased Compensation Arrangement By Sharebased Payment Award Options Forfeited Or Expirations Aggregate Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrExpirationsAggregateIntrinsicValue	2915000	USD
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	115000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.17
CY2020	cdzi	Options Outstanding Balance Average Remaining Contractual Term OptionsOutstandingBalanceAverageRemainingContractualTerm	P0Y4M24D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	919000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	115000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	12.17
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.76
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	-0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	44140
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	11.33
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	15312
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	10.45
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P0Y4M24D
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	919000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y4M24D
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2096000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	562000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	10224
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	12.71
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	49228
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	253654
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.31
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	-0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	149685
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	9.60
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	119281
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	9.10
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	47000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	15000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	15000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	15000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y4M24D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06	pure
CY2020Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	865000	USD
CY2020Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1100000	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-139000	USD

Files In Submission

Name	View Source	Status
0001437749-21-007331-index-headers.html	Edgar Link	pending
0001437749-21-007331-index.html	Edgar Link	pending
0001437749-21-007331.txt	Edgar Link	pending
0001437749-21-007331-xbrl.zip	Edgar Link	pending
cdzi-20201231.xsd	Edgar Link	pending
cdzi-20201231_cal.xml	Edgar Link	unprocessable
cdzi-20201231_def.xml	Edgar Link	unprocessable
cdzi-20201231_lab.xml	Edgar Link	unprocessable
cdzi-20201231_pre.xml	Edgar Link	unprocessable
cdzi20201231_10k.htm	Edgar Link	pending
cdzi20201231_10k_htm.xml	Edgar Link	completed
ex_237060.htm	Edgar Link	pending
ex_237061.htm	Edgar Link	pending
ex_237066.htm	Edgar Link	pending
ex_237068.htm	Edgar Link	pending
ex_237072.htm	Edgar Link	pending
ex_237073.htm	Edgar Link	pending
ex_237074.htm	Edgar Link	pending
ex_237075.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDZI
CADIZ INC Stock $cdzi

2020 Q4 Form 10-K Financial Statement

#000143774921007331 Filed on March 26, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDZI CADIZ INC Stock $cdzi

2020 Q4 Form 10-K Financial Statement

#000143774921007331 Filed on March 26, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDZI
CADIZ INC Stock $cdzi